A Clinical Study Evaluating the Pharmacokinetic Characteristics and Safety of AHB-137 Injection in Participants With Mild to Moderate Liver Dysfunction and Those With Normal Liver Function.

Inclusion Criteria: * Voluntarily participate in the study, sign an informed consent form before the study and be able to complete the study according to the requirements of the protocol; * At the time of signing the informed consent form, male or female participants aged 18-65 years (including threshold values); * Body mass index meets the criteria; * Take effective contraceptive measures as required; * Participants with liver function impairment need to meet certain liver function assessments; * Participants with normal liver function should meet certain age, weight, and gender requirements to match those with liver function impairment, and should also undergo certain physical and laboratory tests. Exclusion Criteria: * Diagnosed or suspected liver cancer participants who have undergone liver transplantation; * History of vasculitis or presence of signs and symptoms of potential vasculitis or laboratory tests; * Unstable control of hypertension or diabetes, progressive nervous system disease, history of immune related extrahepatic diseases, and unstable cardiac function; * Participants with a history of malignant tumors or undergoing malignant tumor assessment; * Screening for participants who have undergone significant trauma or surgery within the previous 3 months, as well as those who plan to undergo surgery; * Participants with thyroid dysfunction who are not suitable for inclusion in the study; * Allergic or allergic constitution to AHB-137; * Long term regular rece…